National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the “Class Period”).
Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .
MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland.
According to the lawsuit, MoonLake and certain executives made false and misleading statements regarding the Company’s only drug candidate, sonelokimab (SLK), in testing as a treatment for certain skin conditions. The complaint alleges that the Company repeatedly promoted SLK’s Nanobody structure as providing superior clinical advantages over traditional monoclonal antibodies, such as FDA-approved BIMZELX.
On September 28, 2025, the Company announced Phase 3 clinical trial results for SLK, which, according to the lawsuit, showed that SLK failed to achieve efficacy comparable to BIMZELX. Analysts reportedly described the data as a “disastrous result,” and MoonLake’s stock declined nearly 90%, or $55.75 per share, in a single trading session.
If you are a MoonLake investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
